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ABSTRACT
DCs orchestrate immune responses contributing to the
pattern of response developed. In cancer, DCs may
play a dysfunctional role in the induction of CD4CD25
Foxp3 Tregs, contributing to immune evasion. We
show here that Mo-DCs from breast cancer patients
show an altered phenotype and induce preferentially
Tregs, a phenomenon that occurred regardless of DC
maturation stimulus (sCD40L, cytokine cocktail, TNF-,
and LPS). The Mo-DCs of patients induced low prolifer-
ation of allogeneic CD3CD25negFoxp3neg cells, which
after becoming CD25, suppressed mitogen-stimulated
T cells. Contrastingly, Mo-DCs from healthy donors in-
duced a stronger proliferative response, a low fre-
quency of CD4CD25Foxp3 with no suppressive ac-
tivity. Furthermore, healthy Mo-DCs induced higher lev-
els of IFN-, whereas the Mo-DCs of patients induced
higher levels of bioactive TGF-1 and IL-10 in cocultures
with allogeneic T cells. Interestingly, TGF-1 blocking
with mAb in cocultures was not enough to completely
revert the Mo-DCs of patients’ bias toward Treg induc-
tion. Altogether, these findings should be considered in
immunotherapeutic approaches for cancer based on
Mo-DCs. J. Leukoc. Biol. 92: 673–682; 2012.
Introduction
DCs are unique, professional APCs adapted to initiate, coordi-
nate, and regulate adaptive immune responses by inducing
naive T cells’ differentiation [1, 2] into Th1 [3], Th2 [4],
Th17 [5], and other CD4 cell subtypes [6]. Recent data sug-
gest that DCs are also crucial for the induction and mainte-
nance of T cell tolerance and have important physiological
roles in the prevention of autoimmunity [7]. Furthermore,
DCs can contribute to the subversion of the immune re-
sponses in cancer [8, 9], in ways that could resemble their role
in maintaining self-tolerance.
It did not take long after the discovery of DCs for their po-
tential in cancer immunotherapy to be recognized [10, 11].
However, as DCs have the potential to induce not only immu-
nity but also immune tolerance, depending on their functional
status [12], many attempts to use DCs in cancer immunother-
apy may have failed to reach all of the expected success as a
result of a possible functional deficit of the cells used. Further,
many studies have demonstrated that DCs are essential for
Treg induction in vitro [13, 14], apparently depending on var-
ious distinct mechanisms [15] but also frequently, on external
sources of cytokines [16].
Optimization of DC differentiation protocols has focused
largely on the capacity of human DCs to improve protective
immunity against cancer [17]; however, their ability to induce
regulatory cells concurrently has received less attention. Tregs
contribute to the maintenance of immunologic self-tolerance
[18] and play a relevant role in immune responses to infec-
tious agents [19, 20]. Harnessing their function could help in
the management of transplantation reactions, whereas their
action can represent an obstacle for successful immunotherapy
in patients with cancer [21, 22]. Although CD8 Tregs have
been described [23], most studies focused on CD4 Tregs.
These have been described on the basis of their origin and
generation [24] and mechanism of action [25]. Inducible
Tregs that are comprised of IL-10-producing Tr1 cells [26],
TGF--producing Th3 cells [27], and inducible Foxp3 T cells
[28], described in different situations, including cancer [29–
31], seem to depend largely on the context of antigen presen-
tation, a phenomenon where DCs play a most relevant role.
DCs are affected by the presence of tumors [32, 33]. Various
observations indicate a deficient functional activity of these
cells with defective stimulation of immune responses as a re-
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sult of a decreased frequency of functionally competent mDCs
(semimature or iDC induction) within tumors. These DCs are
characterized, mainly, by a poor up-regulation of MHC class II
and costimulatory molecules and absent or low-production
proinflammatory cytokines, such as IL-12, thus favoring tumor
evasion from the immune response. Another functional conse-
quence of tumor–DC interactions could be the favoring of the
already-described expansion of CD4CD25Foxp3 Tregs in
patients with solid tumors. Indeed, some studies have shown
the active participation of DCs in the induction of Foxp3 ex-
pression by CD4 T cells in humans [34] and mice [35]. How-
ever, DCs from healthy donors only seem to induce Tregs in
the presence of TGF- [36] or overstimulation with anti-CD3,
anti-CD28, and IL-2.
Although DCs from cancer patients are recognized as func-
tionally deficient, it is not so clear whether Mo-DCs from these
patients show similar deficiencies. Here, we generated DCs
(Mo-DCs) from breast cancer patients and show that these are
strongly biased to the induction of functional Tregs, thus pos-
sibly contributing to the maintenance of a pro-tumor immune
status in the patients and possibly, posing an obstacle for DC-
based therapeutic approaches for cancer.
MATERIALS AND METHODS
Eligibility criteria
Patients, from the Mastology Center at the Perola Byington Hospital (Sao
Paulo, Brazil), with a recent histopathological diagnosis of invasive breast
carcinoma and who had not received chemotherapy, radiotherapy, or im-
munotherapy before study enrollment, were included. Those with uncon-
trolled metastatic lesions in the brain, with hypercalcemia, with other previ-
ous or concomitant neoplasia, who were pregnant or lactating, with auto-
immune diseases, or were HIV-seropositive were excluded from the study.
As controls, we chose healthy, female volunteers over 20 years old. All pa-
tients and healthy volunteers gave written, informed consent. The protocol
was approved by the Institutional Ethics Committee (2009/902 CEP).
DC generation
PBMCs were separated from blood collected in heparin (50 U/ml) by cen-
trifugation over Ficoll-Hypaque (Amersham Pharmacia Biotech, Uppsala,
Sweden). Mononuclear cells were resuspended and seeded in culture six-
well plates in RPMI-1640 culture medium (Gibco, Grand Island, NY, USA),
supplemented with 10% FCS (Gibco) plus antibiotic-antimycotic (100
U/ml penicillin, 100 g/ml streptomycin, and 25 g/ml amphotericin;
Gibco). After that, culture plates were incubated at 37°C overnight. In case
of monocyte use, after overnight incubation, nonadherent cells were re-
moved, and the adhered monocytes were harvested, washed, and used for
the experiments. In case of Mo-iDC use, nonadherent cells were removed,
the medium was replaced, and GM-CSF (50 ng/ml; R&D Systems, Minne-
apolis, MN, USA) and IL-4 (50 ng/ml; R&D Systems) were added. Mo-iDCs
were harvested after 7 days, without any additional manipulation, pheno-
typically characterized, and used in cocultures. Mo-mDCs were harvested at
Day 7, after receiving maturation stimuli at Day 5 with sCD40L (1 mg/mL;
Invitrogen, Carlsbad, CA, USA); a cytokine cocktail containing IL-1 (10
ng/ml; R&D Systems), IL-6 (10 ng/ml; R&D Systems), and TNF- (10 ng/
ml; R&D Systems); only TNF- (50 ng/ml; R&D Systems); or LPS (500 ng/
ml; Escherichia coli 0111:B4; Sigma-Aldrich, St. Louis, MO, USA).
For some experiments, the starting cell population was that of CD14
cells, isolated from PBMCs by magnetic beads (CD14 isolation kit; Miltenyi
Biotec, Germany).
Purification of T cells and isolation of CD25neg cells
CD3 T cells were purified from nonadherent PBMCs by magnetic bead
selection using the CD3 isolation kit (Miltenyi Biotec), reaching over 97%
purity. CD25neg cells were separated from previously CD3-isolated or
CD4 (Miltenyi Biotec) cells by depletion of CD25 cells using the CD25
Microbeads II kit (Miltenyi Biotec) with 98% of purity. Among these
CD3CD25neg and CD4CD25neg cells, 78% were CD45RA. All pheno-
typic analyses were done by flow cytometry.
T cell proliferation by CFSE dilution
Isolated CD3 T cells were labeled with 5 M CFSE and cultivated with
patients or healthy Mo-iDCs. After 5 days, lymphocytes were stained with
anti-CD4 and anti-CD8 antibodies, and CFSE dilution was determined by
flow cytometry analysis. PHA was used as a polyclonal-positive stimulus. At
least 20,000 events were acquired/antibody analyzed.
Mo-DCs and T cell cocultures
Monocytes or Mo-iDCs and Mo-mDCs, after differentiation in vitro (for 7
days), were harvested from plates and cultured with CD3CD25neg or
CD4CD25neg T cells at a 1:10 ratio in RPMI 1640, supplemented with 10%
FCS plus antibiotic-antimycotic solution. No other stimuli were added to
the cocultures. After 6 days of culture, CD3CD25neg or CD4CD25neg T
cells were phenotypically evaluated as to their phenotype (CD4, CD25,
Foxp3, CD127, and CTLA4 expression) or used in functional suppression
assays.
Flow cytometry
Monocytes and DCs. Cell preparations (2.5105 cells/condition) were
labeled with each of the various specific fluorescent antibodies (CD1a,
CD11c, CD14, CD40, CD80, CD86, PD-L1, CD83, CD123, HLA-DR) or iso-
type controls (BD Biosciences, San Jose, CA, USA) and analyzed in the
FACSCalibur cytometer (BD Biosciences) using the FlowJo software, Ver.
7.2.4 (Tree Star, Ashland, OR, USA).
Lymphocytes. Foxp3 expression in T cells was assessed using the anti-
human Foxp3 staining kit (Clone 236A/E7; eBioscience, San Diego, CA,
USA). Mouse IgG1 (BD Biosciences) was used as isotype control in all in-
tracellular staining analyses. Samples were also stained with CD25, CD3,
CD4, CTLA4, CD127, and CD45RA (BD Biosciences). At least 20,000 events
were acquired/antibody analyzed.
Cytokine assay
Coculture supernatants were harvested after 5 days, and IFN- (BD
PharMingen, San Diego, CA, USA), IL-10 (BD PharMingen), and bioactive
TGF-1 (eBioscience) were quantified by sandwich ELISA, according to the
manufacturers ’ instructions. OD was determined in a VersaMax microplate
ELISA reader and converted to pg/ml using a standard curve and SoftMax
Pro software.
Suppression assay
To assess the ability of T cells, generated after cocultures with Mo-iDCs
from patients and controls, to suppress other T cell responses, CD25 cells
were sorted magnetically from cocultures using the CD25 Microbeads II kit
(Miltenyi Biotec) and added to allogeneic, healthy, CFSE-labeled PBMCs
(1105/well) at a 1:10 ratio in 96-well U-bottom plates in the presence of
PHA (1 g/ml) at 37°C and 5% CO2. On Day 3, the cells were harvested,
and the T cell proliferative response was determined by flow cytometry,
evaluating the dilution of CFSE.
TGF- blocking in cocultures
To block TGF- activity in cocultures of Mo-DCs and T lymphocytes, 80
ng/ml neutralizing anti-TGF- (R&D Systems) or control IgG mAb (BD
Biosciences) were added on Day 0 of cultures.
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Statistical analysis
Results were checked for normality by the Kolmogorov-Smirnov test, and
comparisons between results obtained from healthy donors and breast can-
cer patients were performed by a two-tailed unpaired t-test (*P0.05;
**P0.01; ***P0.0001). Effects of neutralizing anti-TGF- were compared
using the paired t-test (*P0.05; **P0.01). Phenotype of monocytes, Mo-
iDCs, and Mo-mDCs was compared using the one-way ANOVA test with the
Tukey post-test.
RESULTS
Mo-iDC cells from patients are phenotypically
different from those derived from healthy donors
Mo-iDCs were generated in vitro from breast cancer patients
(n9) and from healthy donors (n5) by culture for 7 days in
the presence of IL-4 and GM-CSF. Already at the FSC and SSC
profiles of the cells, we noticed that the Mo-iDCs of patients
represented a nonhomogeneous population compared with
the relatively homogeneous cells of healthy donors. On the
other hand, the analysis of CD14 and HLA-DR expression indi-
cated similar frequency of cells with a Mo-iDC phenotype
(CD14-HLA-DR) in both groups (healthy donors: 87.3%0.3
vs. patients: 87.1%3.0; Fig. 1A). Of the molecules evaluated
in DCs, CD80, HLA-DR, and CD11c were not significantly dif-
ferent between healthy donors and patients, but the expres-
sion of CD86 and CD123 clearly distinguished these groups,
both in frequency of positive cells (CD86healthy donors:
37.2%4.0 vs. patients: 74.6%6.5; P0.0001; CD123healthy
donors: 1.90.47 vs. patients: 28.47.16; P0.05) and MFI
(CD86healthy donors: 4.12 vs. patients: 64.444; P0.05;
CD123healthy donors: 10.8 vs. patients: 5.86; P0.05),
whereas for PD-L1, just the MFI distinguished the groups
(healthy donors: 41.530 vs. patients: 190.589.1; P0.05;
Fig. 1A–C). On the other hand, the expression of CD1a was
significantly lower in frequency (healthy donors: 6813 vs. pa-
tients: 38.118; P0.05) and the CD83 activation marker,
lower in MFI (healthy donors: 6816 vs. patients: 33.224;
P0.05) in Mo-iDCs from patients (Fig. 1A–C). Nevertheless,
the maturation status of both cell populations was similar, with
their immature phenotype indicated by low values of MFI for
all costimulatory molecules tested.
In the ELISA assay of the culture supernatants (at Day 5),
for the production of IL-10 and bioactive TGF-1, although
Mo-iDC patients seemed to produce higher levels of the latter
(healthy donors: 107.44.73 pg/ml vs. patients: 203.371.7
pg/ml; P0.05; Fig. 1D), the difference was not significant.
Mo-iDCs from patients induce lower lymphocyte
activation and proliferation but higher proportions of
CD4CD25Foxp3 cells
To investigate further the possible functional deviation of the
Mo-iDCs of patients, our next step was the analysis of their
ability to activate and stimulate lymphocyte proliferation in
Figure 1. Mo-iDCs from cancer patients are more heterogeneous, express high levels of CD86, CD123, and PD-L1, and produce IL-10 and TGF-
1. Monocytes from healthy donors and from cancer patients were cultured in the presence of IL-4 and GM-CSF for 7 days and characterized.
Flow cytometry analysis of Mo-iDCs (CD14low/HLA-DR cells) from healthy donors and breast cancer patients showing: (A) frequency of cells posi-
tive for characteristic markers, (B) representative histograms, and (C) MFI values for the markers; (D) ELISA assay of Mo-iDC supernatants for the
presence of IL-10 and bioactive TGF-1 (healthy donors, n5; patients, n9; *P0.05; ***P0.0001).
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vitro. Allogeneic CD3 lymphocytes were labeled with CFSE and
cocultivated with Mo-iDCs for 5 days (at a 10:1 lymphocyte:DC
ratio). After that, cells were recovered and labeled with
anti-CD4 and anti-CD8 antibodies and their proliferation ana-
lyzed by CFSE dilution. Analysis of nonstimulated and PHA-
stimulated lymphocytes indicated 16% and 77% of CD4
proliferation and 12% and 76% of CD8 proliferation, re-
spectively. Mo-iDCs from healthy donors induced higher fre-
quency (healthy donors: 57%12 vs. patients: 24.1%6.6;
P0.01) and absolute number (healthy donors: 7.9104
5.3103 vs. patients: 6.31043.3103; P0.01) of proliferating
CD4 lymphocytes (Fig. 2A–C). Similar differences were ob-
served in CD8 lymphocyte stimulation, also in frequency
(healthy donors: 60%13.8 vs. patients: 22.86.5%; P0.05) and
absolute number (healthy donors: 8.071047.5103 vs. pa-
tients: 6.141043.2103; P0.05), comparing Mo-iDCs from
healthy donors and breast cancer patients (Fig. 2A–C).
When Mo-iDCs were used to stimulate allogeneic CD3CD25neg
lymphocytes, cells from patients induced the expression of the CD25
activation marker in significantly less lymphocytes than Mo-iDCs
from healthy donors (healthy donors: 35.7%7.9 vs. patients:
11.8%5.9; P0.0001). This was also reflected in the total cell count
in these conditions (patients: 8.0410510.8105 vs. healthy do-
nors: 34.810511.3105; P0.01; Fig. 2D–F).
Furthermore, Mo-iDCs from cancer patients induced a sig-
nificantly higher occurrence of CD4Foxp3 among the
CD25 fraction of allogeneic cocultured T cells compared
with those induced by the healthy Mo-iDC donors: healthy,
2.5%0.7 (1.01056.6104), vs. patient, 56.8%4.1
(4.61053.1105; Fig. 3A and B). To exclude possible non-
DCs contaminating the cultures, we differentiated Mo-iDCs
from CD14-preisolated cells. In coculture with allogeneic T
lymphocytes, these induced the same Treg frequency as the
nonisolated population (Fig. 3C). Accordingly, cocultures with
patient Mo-iDCs showed increased concentrations of IL-10
(healthy donors: 14.02.6 pg/ml vs. patients: 61.828.1 pg/
ml; P0.05) and bioactive TGF-1 (healthy donors: 57.63.3
pg/ml vs. patients: 298.1129 pg/ml; P0.05), whereas those
with healthy Mo-iDC donors presented higher levels of IFN-
(healthy donors: 471.8620 pg/ml vs. patients: 14.815.6 pg/
ml; P0.05; Fig. 3D).
Tregs induced by Mo-iDCs from cancer patients
showed a reduced proliferative activity in the
cocultures and are able to suppress T lymphocyte
responses to PHA
T lymphocytes were separated, labeled with CFSE, and cocul-
tured with Mo-iDCs. After 6 days, proliferation was evaluated
by CFSE dilution within Foxp3 and Foxp3neg cells. As ex-
pected, proliferation of Foxp3 cells was significantly lower
than that of Foxp3neg cells in healthy Mo-DC-stimulated cul-
tures of donors and patients (Fig. 4A). Higher expression of
the CTLA4 molecule, a characteristic Treg marker, was also
observed in gated CD4CD25Foxp3 cells in healthy Mo-DC
cocultures of donors and patients compared with the Foxp3neg
population (Fig. 4A, bottom graphs).
Figure 2. The Mo-iDCs of patients induce low proliferation and CD25 expression by allogeneic T cells. Mo-iDCs from controls and patients were
cocultured with allogeneic CFSE-labeled CD3 or CD3CD25neg cells for 5 days. At the end of culture, CFSE dilution and CD25 expression by
CD3 cells were evaluated by flow cytometry. (A) Representative experiment of CFSE dilution in CD4 and CD8 T cells. FL1, Fluorescence 1.
(B) Pooled data from five independent experiments showing frequency of cells with CFSE dilution and (C) absolute number of dividing cells
(n5; *P0.05; **P0.01). (D) Representative experiment showing CD25 expression by CD3 cells after coculture of CD3CD25neg lymphocytes
with Mo-iDCs from healthy donors or from breast cancer patients. (E) Average frequency and (F) absolute number of CD25 cells in six indepen-
dent experiments (n6; **P0.01; ***P0.0001).
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To test the suppressive function of lymphocytes stimulated
by different Mo-iDCs, CD25 cells were isolated by magnetic
microbeads (97% of purity) from the healthy Mo-iDC–T cell
cocultures of patients and added (at a 1:10 ratio) to allogeneic
PBMCs, previously labeled with CFSE and stimulated with
PHA. After 3 days in culture, cells were analyzed by cytometry
for CFSE dilution. CD25 cells from the Mo-iDC–T cocultures
of patients inhibited mitogen-induced T cell proliferation,
whereas cells from the healthy coculture of donors were stimu-
latory in the same settings (Fig. 4B and C).
TGF- neutralization with mAb partially inhibits Treg
induction by Mo-iDCs from breast cancer patients
TGF- is recognized as a relevant cytokine for the induction of
Tregs and is produced in high levels by Mo-DCs from breast
cancer patients. Therefore, we tested whether a neutralizing
antibody against this cytokine was able to inhibit Treg genera-
tion by Mo-DCs from patients cocultured with allogeneic
CD4-isolated lymphocytes. Indeed, the Mo-iDC–T cell cocul-
tures of patients treated with the neutralizing antibody pre-
sented significantly higher cell proliferation (Fig. 5A), without
reducing the induced CD25 T cell proportion (Fig. 5B). Be-
yond that, the presence of anti-TGF- antibodies also led to
significantly lower frequency (Fig. 5C) and absolute number
(Fig. 5D) of CD4CD25Foxp3CD127low cells in cocultures,
however, not in a similar frequency to levels induced by
healthy Mo-iDCs.
DCs differentiated from the monocytes of breast
cancer patients present a bias for the induction of
Tregs even after maturation stimulus
Maturation of DCs is associated with a decrease in their ability
to induce regulation. Therefore, monocytes and Mo-iDCs and
sCD40L, cocktail, TNF-, and LPS-treated Mo-iDCs from breast
cancer patients were used as stimulators of allogeneic T cells
to analyze the generation of CD4CD25Foxp3 cells. The
phenotypic analysis demonstrated the dynamic increase of
molecules (MFI) during monocyte-to-Mo-DC differentiation
(Fig. 6A). In functional assays, healthy Mo-mDCTNF-induced a
higher frequency of CD25 cells (Fig. 6B) and lower fre-
quency (Fig. 6C) and absolute number (Fig. 6D) of
CD4CD25Foxp3 cells, as compared with all groups of the
activated Mo-mDCs of patients. Moreover, analysis between the
APCs of patients showed a reduced ability of monocytes to in-
duce CD4CD25Foxp3 in comparison with Mo-iDCs and all
Mo-mDC groups in frequency and absolute number (Fig. 6C
and D). Regarding the activation status between Mo-DCs from
patients, Mo-mDCsLPS were the only ones capable of signifi-
cantly increasing the frequency of CD25 cells (Fig. 6B) and
reducing CD4CD25Foxp3 frequency (Fig. 6C) in relation
to the ability of Mo-iDCs; however, the absolute number of
CD4CD25Foxp3 induced was not altered (Fig. 6D). Fur-
thermore, the absolute number of induced Tregs was not dif-
ferent, comparing all activation stimulus used in the Mo-iDCs
of patients (Fig. 6D), failing to revert the bias present in those
cells.
DISCUSSION
We show here that Mo-DCs from cancer patients have a bias
toward the induction of Tregs, a characteristic that is bound to
impair the effectiveness of any therapeutic trial based on the
cells of these patients. Indeed, Tregs are recognized as central
in the maintenance of tolerance to self [37] but may also be
involved in the failure of the immune system to eliminate or
control infections [19, 20] and tumors [21] and to respond to
Figure 3. The Mo-iDCs of patients induce high frequency of CD4CD25Foxp3
cells, low IFN-, high IL-10, and TGF-1 production in cocultures with allogeneic T
cells. Mo-iDCs from controls and patients were cocultured with allogeneic CD3
and CD3CD25neg cells for 6 days. At the end of culture, the phenotype of the T
cells was evaluated by flow cytometry and the production of cytokines by ELISA. (A)
Representative zebra plots showing the frequency of CD4CD25Foxp3 after 6-day
cultures among unstimulated T lymphocytes or T lymphocytes cocultured with Mo-iDCs from healthy donors or from breast cancer patients. (B) Absolute num-
ber and (C) average frequency of CD4CD25Foxp3 cells in 6-day cocultures of allogeneic T cells with iDCs differentiated from adherent monocytes (n6) or
from CD14-preisolated monocytes obtained from healthy donors or from breast cancer patients (n3; *P0.05; ***P0.0001). (D) ELISA assays of coculture
supernatants for the presence of: IL-10, bioactive TGF-1, and IFN- (n5; *P0.05).
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therapeutic vaccination [22]. Thus, the optimization of the DC
phenotype, when these are used for therapeutic vaccination in
cancer, is a crucial point for the achievement of better clinical
responses.
Here, we induced the differentiation of blood monocytes
obtained from breast cancer patients and from healthy donors
into DCs, cultivating blood precursors in the presence of
GM-CSF and IL-4, an established protocol for the generation
of Mo-DCs [38]. Interestingly, under phase-contrast micros-
copy (data not shown) and by flow cytometry, Mo-iDCs, ob-
tained from patients, presented a distinct morphology, being
quite heterogeneous in FSC and SSC. On other hand, the fre-
quency of cells within the FSC and SSC gate characteristic of
DCs was similar between patients and healthy donors, as was
the frequency of CD14negHLA-DR cells within these gates,
suggesting, thus, that the overall differentiation process was
not affected significantly in the cells of cancer patients.
Although the frequency of Mo-iDCs was similar, cells derived
from patients showed a higher frequency of CD86 costimula-
tory molecule expression and the classical plasmacytoid
marker, CD123. Furthermore, whereas cells derived from
healthy donors presented a single population of CD86 cells,
with intermediate fluorescence intensity, those derived from
patients seemed to be divided in two subpopulations: one with
high and the other with low levels of CD86 expression. In-
deed, the modulation of costimulatory molecules in APCs, par-
ticularly in DCs, seems to be essential to initiate and coordi-
nate the nature of T cell responses [1]. CD86 and CD80 bind
to stimulatory (CD28) and inhibitory (CTLA4) receptors on T
cells with different affinities [39]. In human DCs, the induc-
tion and up-regulation of CD86 were shown to influence T
cell activation significantly [40], whereas studies in knockout
mice have indicated that the ability of DCs to generate/ex-
pand Treg subsets can be related to the balance of CD80 and
CD86 [41, 42]. Our data indicate that the Mo-iDCs of patients
present an altered CD86 pattern of expression and are poor T
cell activators but very good Treg expansors/activators, sug-
gesting that the modulation of costimulatory molecule expres-
sion could, indeed, be a pathway for the deviation of DC func-
tion in cancer patients. Actually, we have already observed an
altered expression of CD86 in Mo-DCs from advanced cancer
patients that was, apparently, corrected by an immunothera-
peutic approach [9]. Simultaneously, we also need to consider
the higher MFI expression of PD-L1 in Mo-iDCs from cancer
Figure 4. The Mo-iDC-induced CD4CD25Foxp3 cells of patients proliferate poorly and
have suppressive function upon mitogen-stimulated T lymphocytes. (A) Mo-iDCs from healthy
donors or from cancer patients were cocultured for 6 days with CFSE-labeled (lab.) T lympho-
cytes. CFSE dilution and CTLA4 expression were evaluated among CD4CD25Foxp3 and
Foxp3neg cells (one representative experiment of three). Mo-iDCs-induced (ind.) CD25 cells
were isolated and added to allogeneic, PHA-stimulated, CFSE-labeled cells (one sorted CD25
cell: 10 CFSE-labeled PBMC) and cultured for 3 days. (B) Representative experiment and (C)
pooled data from four experiments showing CFSE dilution of PHA-stimulated PBMCs under
the influence of CD4CD25Foxp3 obtained from cocultures with Mo-iDCs from healthy do-
nors or from breast cancer patients (n4; ***P0.0001).
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patients as possibly involved in the tolerogenic function of
these cells, as in murine models, the expression of this mole-
cule by DCs has been related to Foxp3 Treg via the PD-1R
[43]. Interestingly, in humans, recent studies describe PD-L1
overexpression by peritumoral monocytes [44] and by tumor
cells [45]. Furthermore, the high expression of CD123 mole-
cules deserves investigation, as it has been reported that
CD123 expression is related to a high expression of IDO,
which confers a tolerogenic function to human myeloid DCs
[46] and seems to be involved in the recruitment of Foxp3
cells to ovary tumor sites [47]. Therefore, although the ability
of DCs to induce Treg activation depends on the balance of
these various costimulatory molecules [48], the exact role of
the balance between these molecules, mainly in human DCs
and particularly, in cancer patients, is still unclear.
Additionally to the membrane phenotype differences, IL-10
and bioactive TGF-1 cytokine production by the Mo-iDCs of
patients were also characteristic, as elevated levels of both of
these suppressor cytokines were found in their culture super-
natants when compared with healthy Mo-iDCs. These cytokines
are also involved in the commitment of näive T cells to sup-
pressive properties [49], with IL-10 involved in the generation
of Tr1 cells and TGF- in the generation of Th3 Foxp3 cells.
TGF- is a multifunctional cytokine that regulates T cell
growth and development [50], inhibits IL-2 production, and
has potent, antiproliferative effects on CD4 T cells [51], prin-
cipally by inducing Tregs [28, 36, 52], thus providing a possi-
ble explanation for the preferential generation/expansion of
Tregs by Mo-iDCs from cancer patients. Indeed, the addition
of a neutralizing antibody against this cytokine in cocultures of
the Mo-DCs of patients and allogeneic T cells allowed a signifi-
cantly higher proliferation of T cells, which also presented a
significantly lower frequency of CD4CD25Foxp3 cells. It is
noteworthy, though, that the addition of the neutralizing anti-
TGF-1 antibody was not enough to completely revert the in-
duction of Tregs by the Mo-DCs of patients, thus suggesting
the contribution of more than one mechanism for the genera-
tion of Tregs by the Mo-DCs of patients.
It is noteworthy that the CD25 cells, generated by cocul-
ture with the Mo-iDCs of patients, were able to suppress a mi-
togen-induced T cell proliferation, in contrast with CD25
cells stimulated by healthy donor Mo-iDCs that had no sup-
pressive activity. Considering that the CD25 marker selected
activated cells and Tregs, we thus confirm the suppressive ac-
tivity of CD25Foxp3 lymphocytes induced by the Mo-iDCs
of patients in vitro. Indeed, Foxp3 T cells are phenotypically
and functionally heterogeneous and may contain Foxp3low
non-Tregs (30–50% of total CD4Foxp3 T cells) that can
produce proinflammatory cytokines [53], a phenomenon that
could explain the lack of suppressive activity by these cells
when induced by the healthy DCs of donors.
Although interesting, these data could still be considered
less significant, as the bias was noted when Mo-iDCs were stud-
ied, a population whose ability to induce Tregs has long been
described [13, 14]. Furthermore, as Mo-mDCs are used in
therapeutic protocols for cancer, one could argue that the
phenotype of immature cells is of lesser relevance. Notwith-
standing the fact that the bias was noted when immature cells
of healthy controls and patients were compared, thus indicat-
ing a phenomenon beyond the simple maturation status of the
cell, we decided to induce the Mo-DCs of the maturation of
patients (using sCD40L, a cytokine cocktail, TNF-, and LPS)
and then, evaluate their ability to induce Tregs, also compar-
ing it with that of monocytes. In these experiments, we noted
Figure 5. Neutralizing antibodies to TGF-1 in cocultures of
allogeneic T cells and the Mo-iDCs of patients allow a more
intense proliferation and partially inhibit CD4CD25Foxp3
T cell generation. Mo-iDCs from breast cancer patients were
cocultured with allogeneic CD4CD25neg T cells in the pres-
ence of 80 ng/ml neutralizing anti-TGF-1 antibodies or con-
trol mAb. After 6 days, cells were harvested, counted, and labeled for flow cytometry. (A) Box and whisker plot showing absolute cell numbers recovered
in cultures. (B) CD25 expression by stimulated T lymphocytes. (C) CD4CD25Foxp3CD127low cell frequency and (D) absolute numbers among recov-
ered cells (healthy donors, n4; patients, n6; *P0.05; **P0.01; ***P0.0001).
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that Mo-mDCs from patients conserved the bias toward the
induction of a similar number of Tregs, indicating the exis-
tence of a profound alteration of the monocytes of patients,
which cannot be corrected easily by standard culture proto-
cols. Besides that, it is also relevant that monocytes from
healthy donors and from patients initially present a similar
capacity to induce CD4CD25Foxp3 T lymphocytes. This
capacity, however, decreases in the cells of healthy donors, as
they differentiate toward DCs (as one would expect), but in-
creases in cells of patients.
Figure 6. Treg-induction bias of the Mo-DCs of patients is maintained after
maturation induced by different stimuli. Monocytes (Mono), Mo-iDCs
(generated by culture in the presence of GM-CSF and IL-4 for 7 days), and
Mo-mDCs [Mo-iDCs stimulated with sCD40L, IL-1IL-6TNF- (Cockt.),
TNF-, or LPS on Day 5] were analyzed at Day 7 by flow cytometry and
used as stimulators of allogeneic T cells. After 6 days of allogeneic cocul-
tures, the induction of the CD4CD25Foxp3 cell was determined by
flow cytometry. (A) Average MFI of CD86, CD80, CD83, CD40, and
HLA-DR. (B) Average level of CD25 expression. (C) Average frequency of
CD4CD25Foxp3 cells and (D) absolute number of CD4Foxp3 in
gated CD25 cells. (Healthy donors: monocyte, n3; Mo-iDC, n5; Mo-
mDCTNF-, n4; and patients: monocyte, n3; Mo-iDC, n8; Mo-
mDCCD40L, n3; Mo-mDCscocktail, n3; Mo-mDCsTNF-, n4; Mo-mDCsLPS,
n3. Comparison between healthy vs. patient: *P0.05; **P0.01;
***P0.0001; comparison among patients’ groups: #P0.05; ##P0.01;
###P0.0001.)
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Taken together, our data show important differences in phe-
notype and function of DCs derived from cancer patient
monocytes that appear to be dependent of their surface phe-
notype and pattern of cytokine induction/production. These
features could have a definitive role in the tumor-escape
mechanism. If the apparent bias of Mo-DCs from cancer pa-
tients cannot be corrected by targeted in vitro manipulations,
the effectiveness of cancer vaccination strategies based on
these cells would probably be compromised significantly.
On the other hand, the determination of the mechanisms,
through which tumors are able to modify the circulating abil-
ity of monocytes to differentiate in vitro into DCs, could point
to new, tumor-escape strategies, whose identification could
provide new targets to be considered in immunotherapeutic
approaches to cancer.
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